Since the publication of my article "Why Novartis Remains A 'Buy' After Beating Expectations Again," Novartis' ( NVS ) stock price has risen by over 15%, thus not only hitting its 52-week high but also reaching its new historic peak, thanks toWith over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodit ...